Rigel wins patents in key disease areas

Specifically, Rigel has been granted six patents in immunology, five patents related to its ubiquitin ligase technology, four patents related to hepatitis-C, six patents in oncology, four patents towards its library screening technology, and four patents in Fluorescence- Activated Cell Sorter (FACS) technology.

The ligase patents cover methods for identifying and/or measuring ubiquitin ligase activity in any disease state and screening for agents that modulate their activity using any of the major enzymes in the ligase pathway as well as particular enzymes.

“Rigel remains on the forefront of ligase research, and has significant research and development expertise in immunology, virology and oncology where we have been identifying and developing novel, small-molecule drugs,” said Dr Donald Payan, executive vice president and chief scientific officer of Rigel. “The large number of patents we have received over the past year exemplifies our productivity in these key disease areas.”